Arzneimittelwerk Vida AG (TLIK)
XDUS Summary
TLIK Chart
Arzneimittelwerk Vida AG (TLIK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arzneimittelwerk Vida AG ever had a stock split?
Arzneimittelwerk Vida AG Profile
| Communications Equipment Industry | Information Technology Sector | Sascha Knoche CEO | XDUS Exchange | DE000A289B07 ISIN |
| DE Country | 2 Employees | 1 Sep 2008 Last Dividend | 10 Jul 2020 Last Split | - IPO Date |
Overview
TELES Aktiengesellschaft, founded in 1983, is a prominent player in the pharmaceutical industry with global operations extending beyond its headquarters in Berlin, Germany. The company has carved out a significant presence in the field by focusing on the development, manufacturing, and distribution of pharmaceutical products aimed at addressing some of the most challenging medical conditions. TELES Aktiengesellschaft has cultivated a reputation for innovation and excellence in the healthcare sector, providing critical therapeutic solutions to patients around the world in areas such as oncology, neurology, ophthalmology, hemophilia, and autoimmune and infectious diseases.
Products and Services
- Oncology:
TELES Aktiengesellschaft offers a range of products designed to treat various forms of cancer, providing patients with essential medications that aim to improve survival rates and quality of life. This includes chemotherapeutics and targeted therapies that address specific cancer types.
- Neurology:
The company produces treatments for neurological disorders, focusing on medication that aids in managing conditions like multiple sclerosis and Parkinson's disease. These products support the functioning of the nervous system and help alleviate the symptoms experienced by patients.
- Ophthalmology:
In the field of ophthalmology, TELES Aktiengesellschaft develops and markets products aimed at treating eye conditions such as glaucoma and macular degeneration. These products are crucial in preserving vision and preventing blindness.
- Hemophilia:
TELES provides therapies for patients with hemophilia, a rare genetic disorder that affects blood clotting. The company’s range of products includes clotting factor replacements that are essential for the management of this condition.
- Autoimmune and Infectious Diseases:
The company extends its portfolio to include treatments for autoimmune and infectious diseases, offering immunosuppressants and antivirals, respectively. These products are vital in managing chronic and acute conditions, improving patient outcomes and quality of life.
